|1.||Sehested, Maxwell: 8 articles (01/2013 - 08/2006)|
|2.||Knoblauch, Poul: 4 articles (08/2015 - 02/2008)|
|3.||Yeo, Winnie: 4 articles (01/2013 - 04/2010)|
|4.||Jensen, Peter Buhl: 4 articles (01/2013 - 07/2007)|
|5.||Petersen, Kamille Dumong: 4 articles (09/2009 - 08/2006)|
|6.||Ara, Gulshan: 4 articles (03/2008 - 08/2006)|
|7.||Qian, Xiaozhong: 4 articles (03/2008 - 08/2006)|
|8.||O'Connor, Owen A: 3 articles (08/2015 - 01/2010)|
|9.||Chawla, Shanta: 3 articles (08/2015 - 01/2013)|
|10.||Rajan, Arun: 3 articles (11/2014 - 05/2011)|
01/01/2015 - "Several clinical trials are currently investigating the use of belinostat in different cancers and in combination with other chemotherapeutic agents."
07/01/2011 - "In this study, we aimed to determine the effectiveness of volumetric response evaluation criteria in solid tumors (volumetrics) for evaluating response in patients with thymic malignancies treated on a phase II study of belinostat. "
05/20/2011 - "Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors."
09/01/2008 - "Sixteen patients received belinostat at one of three dose levels: 600 mg/m(2)/d (three patients), 900 mg/m(2)/d (three patients) and 1000 mg/m(2)/d (10 patients), the dose determined to be the MTD in a phase I solid tumor study [Steele et al. (2008) Clin Cancer Res, 14, 804-10]. "
05/01/2008 - "The threshold level for belinostat activity, indicated by acetylated H4, correlated with belinostat plasma concentrations above 1,000 ng/ml. In conclusion, examination of H4 acetylation in fine needle biopsies using the T25 antibody may prove useful in monitoring HDAC inhibitor efficacy in clinical trials involving humans with solid tumors."
|2.||Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
08/10/2015 - "Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study."
12/01/2011 - "The data from these studies were analysed to summarise the progress of belinostat from Phase I to a current pivotal trial in peripheral T-cell lymphoma. "
08/01/2015 - "Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review."
06/15/2015 - "FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma."
01/01/2015 - "Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma."
02/15/2012 - "In this study, we show that belinostat, an HDAC inhibitor with an alternative chemical scaffold, also caused a rise in cellular PC content that was detectable by (1)H and (31)P MRS in prostate and colon carcinoma cells. "
05/15/2015 - "Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial."
05/01/2012 - "A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study."
05/15/2015 - "The objective of this study was to evaluate the efficacy of belinostat, a histone deacetylase inhibitor, when added to paclitaxel/carboplatin in the empiric first-line treatment of patients with carcinoma of unknown primary site (CUP). "
08/15/2014 - "Belinostat approved for use in treating rare lymphoma."
12/01/2011 - "Belinostat: clinical applications in solid tumors and lymphoma."
01/01/2013 - "Belinostat, a histone deacetylase (HDAC) inhibitor, has demonstrated broad antineoplastic activity in preclinical studies, and promising results in advanced relapsed/refractory lymphomas.Here"
12/01/2011 - "Belinostat is one member of the class that has been tested as a single agent and in combination with other chemotherapies and biological agents in the treatment of solid tumors and lymphoma. "
06/01/2015 - "Further, this review presents the clinical outcomes of vorinostat, romidepsin, and belinostat, which are approved by the United States Food and Drug Administration for the treatment of lymphomas. "
|5.||Colonic Neoplasms (Colon Cancer)
08/01/2011 - "In this study, we investigated the antitumor effect of PXD101 combined with irinotecan in colon cancer. "
08/01/2011 - "These data show that PXD101 increases the cytotoxic activity of irinotecan in in vitro and in vivo colon cancer models and suggest these agent combinations should be explored in the treatment of colon cancer."
08/01/2011 - "[(18)F]FLT-PET was used to detect early responses to PXD101 and irinotecan in colon cancer. "
08/01/2011 - "HCT116 and HT29 colon cancer cells for cell viability assay were treated with PXD101 and/or SN-38, the active form of irinotecan. "
08/01/2010 - "Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat."
|1.||Histone Deacetylase Inhibitors
|3.||Histone Deacetylases (Histone Deacetylase)
|10.||vorinostat (suberoylanilide hydroxamic acid)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)